Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell

Cellular Immunology

Volumn 271, Issue 1, 2011, Pages 118-123

  Wu, Chenxuan ^a   Guo, Hongxing ^b   Wang, Yijun ^a   Gao, Yingtang ^a   Zhu, Zhengyan ^a   Du, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

4 1BBL; Costimulation; Cytotoxic T lymphocyte; Dendritic cell; Hepatocellular carcinoma

Indexed keywords

RECOMBINANT PROTEIN; RECOMBINANT PROTEIN 4 1BBL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EXTRACELLULAR MATRIX; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

4-1BB LIGAND; ANTIGENS, CD137; BINDING SITES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HEP G2 CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; K562 CELLS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 80052351833     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.06.013     Document Type: Article

References (38)

1. Aalamian-Matheis M., Chatta G.S., Shurin M.R., Huland E., Huland H., Shurin G.V. Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA. Adv. Exp. Med. Biol. 2007, 601:173-182.
2. Kyte J.A., Mu L., Aamdal S., Kvalheim G., Dueland S., Hauser M., Gaudernack G., et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006, 13(10):905-918.
3. Nakamoto Y., Mizukoshi E., Tsuji H., Sakai Y., Kitahara M., Arai K., et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin. Exp. Immunol. 2007, 147(2):296-305.
4. Palmer D.H., Midgley R.S., Mirza N., Torr E.E., Ahmed F., Steele J.C., Young L.S., Adams D.H., et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009, 49(1):124-132.
5. Butterfield L.H., Ribas A., Dissette V.B., Lee Y., Yang J.Q., De la Rocha P., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 2006, 12(9):2817-2825.
6. Wierecky J., Müller M.R., Wirths S., Halder-Oehler E., Dörfel D., Schmidt S.M., et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006, 66(11):5910-5918.
7. Butterfield L.H., Ribas A., Potter D.M., Economou J.S. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP positive hepatocellular cancer. Cancer Immunol. Immunother. 2007, 56(12):1931-1943.
8. Parajuli P., Sloan A.E. Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest. 2004, 22(3):405-416.
9. Alderson Mark R., Smith Craig A., Tough Teresa W., Davis-Smith Terri, Armitage Richard J., Falk Ben, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 1994, 24(9):2219-2227.
10. Cheuk A.T., Mufti G.J., Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004, 11(3):215-226.
11. Choi B.K., Kim Y.H., Kang W.J., Lee S.K., Kim K.H., Shin S.M., et al. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 2007, 67(18):8891-8899.
12. Gray J.C., French R.R., James S., Al-Shamkhani A., Johnson P.W., Glennie M.J. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol. 2008, 38(9):2499-2511.
13. Yoshida M., Jo J., Tabata Y. Augmented anti-tumor effect of dendritic cells genetically engineered by interleukin-12 plasmid DNA. J. Biomater. Sci. Polym. Ed. 2010, 21(5):659-675.
14. Stewart T.J., Smyth M.J. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011, 30(1):125-140.
15. Gajewski T.F., Fuertes M., Spaapen R., Zheng Y., Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 2011, 23(2):286-292.
16. Gervais A., Toutirais O., Bouet-Toussaint F. In vitro antitumor lymphocyte generation using dendritic cells and innate immunity mechanisms as tumor cell treatments. Anticancer Res. 2007, 27(4B):2385-2392.
17. Ganguly S., Liu J., Pillai V.B., Mittler R.S., Amara R.R. Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine 2010, 28(5):1300-1309.
18. Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010, 2(3):233-255.
19. Jiang W.G., Xiong D.S., Shao X.F., Wang J.H., Xu Y.F., Liu F., et al. Cloning and expression of the extracellular domain of 4-1BBL. Sheng Wu Gong Cheng Xue Bao 2005, 21(5):703-707. in Chinese.
20. Guo H., Jiang W., Liu W., Gao Y., Yang M., Zhou Y., et al. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3×anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Cell Immunol. 2008, 251(2):102-108.
21. Sanarico N., Ciaramella A., Sacchi A., Bernasconi D., Bossù P., Mariani F., et al. Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. J. Leukoc. Biol. 2006, 80(3):555-562.
22. Schnurr M., Galambos P., Scholz C., Then F., Dauer M., Endres S., et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001, 61(17):6445-6450.
23. Powell D.J., Levine B.L. Adoptive T-cell therapy for malignant disorders. Haematologica 2008, 93(10):1452-1456.
24. Ju S.A., Cheon S.H., Park S.M., Tam N.Q., Kim Y.M., An W.G., et al. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int. J. Cancer 2008, 22(12):2784-2790.
25. Choi B.K., Kim Y.H., Kwon P.M., Lee S.C., Kang S.W., Kim M.S. 4-1BB functions as a survival factor in dendritic cells. J. Immunol. 2009, 182(7):4107-4115.
26. Wilcox R.A., Chapoval A.I., Gorski K.S., Otsuji M., Shin T., Flies D.B., et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J. Immunol. 2002, 168(9):4262-4267.
27. Scholl N., Loibl J., Kremser A., Liepert A., Grabrucker C., Salih H.R., et al. The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. Leuk. Lymphoma 2009, 50(3):427-436.
28. Houtenbos I., Westers T.M., Dijkhuis A., de Gruijl T.D., Ossenkoppele G.J., van de Loosdrecht A.A. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clin. Cancer Res. 2007, 13(1):307-315.
29. Lee J., Dollins C.M., Boczkowski D., Sullenger B.A., Nair S. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology 2008, 125(2):229-240.
30. Futagawa Toshiro, Akiba Hisaya, Kodama Tomohiro, Takeda Kazuyoshi, Hosoda Yasuyuki, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 2002, 14(3):275-286.
31. Sharma R.K., Elpek K.G., Yolcu E.S., Schabowsky R.H., Zhao H., Bandura-Morgan L., et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res. 2009, 69(10):4319-4326.
32. Algarra I., García-Lora A., Cabrera T., Ruiz-Cabello F., Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 2004, 53(10):904-910.
33. Lu Z.Y., Condomines M., Tarte K., Nadal L., Delteil M.C., Rossi J.F., et al. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp. Hematol. 2007, 35(3):443-453.
34. Yi K.H., Nechushtan H., Bowers W.J., Walker G.R., Zhang Y., Pham D.G., et al. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res. 2007, 67(20):10027-10037.
35. Müller D., Frey K., Kontermann R.E. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J. Immunother. 2008, 31(8):714-722.
36. Lin G.H., Liu Y., Ambagala T., Kwon B.S., Ohashi P.S., Watts T.H. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One 2010, 5(6):e11003.
37. Gerner M.Y., Casey K.A., Mescher M.F. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J. Immunol. 2008, 181(1):155-164.
38. Kass R., Bellone S., Palmieri M., Cane S., Bignotti E., Henry-Tillman R., et al. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res. Treat. 2003, 80(3):275-285.